Probiotics nudged spine bone density, not bone markers

Gut microbiota has been implicated in bone health, which raises an obvious question: can swallowing live bacteria measurably change the skeleton? Bone mineral density is the standard yardstick for skeletal strength, and it declines with age, particularly after the menopause. Individual probiotic trials have been small, used different strains and reported mixed results, so no clear picture has emerged. The authors set out to appraise, both qualitatively and quantitatively, how much skeletal benefit the randomised evidence actually supports.

The team searched PubMed, Web of Science and the China National Knowledge Infrastructure for randomised controlled trials reporting bone mineral density, C-terminal telopeptide of type 1 collagen (CTX) or procollagen type 1 N-propeptide (P1NP). Results were combined using a random-effects model to generate pooled weighted mean differences with 95% confidence intervals. Different numbers of trials contributed to each outcome: 16 for lumbar spine areal BMD, 9 for hip, 7 for femoral neck, 10 for P1NP and 11 for CTX. Most of the included trials had enrolled postmenopausal women, and the authors ran subgroup and trial-exclusion analyses to test how stable the pooled results were.

Probiotic supplementation significantly increased lumbar spine areal BMD (+0.010) and hip areal BMD (+0.022 g/cm2). There was no significant effect on femoral neck areal BMD, nor on either bone turnover marker, P1NP or CTX. Moderate-to-high heterogeneity was present in all analyses, which the authors attribute to differences in participants and interventions. The lumbar spine gain held up regardless of which trials were excluded, whereas the hip result lost significance when key trials were omitted, and restricting analyses to postmenopausal women gave results consistent with the main findings.

This extends earlier microbiome-and-bone work from mechanism into pooled human outcomes, but the size of the benefit is best described as modest. The absence of any change in P1NP or CTX is notable, because those markers are usually where a genuine shift in bone remodelling shows up first. The analysis cannot say which strains, doses or durations matter, since heterogeneity between trials was substantial. It also leaves the outcome that matters most untested here: no fracture data were pooled, so whether these density changes translate into fewer broken bones remains open.

This is a reason to think probiotics may have a small, real effect on spine bone density, most clearly in postmenopausal women, rather than a dramatic one. The evidence is strongest at the lumbar spine and shakier at the hip, and it does not extend to the femoral neck at all. Because bone turnover markers did not move, the mechanism behind the density change is not settled by this analysis. Anyone thinking about bone health can read this as one modest input alongside the far better-established levers, not as a replacement for them.